Lege Artis Medicinae

[Natural Immunity Lóránd Bertók, Donna A. Chow: Natural Immunity.]

PÁLÓCZI Katalin

APRIL 21, 2006

Lege Artis Medicinae - 2006;16(04)

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[ENDOSCOPIC AND INTRAVENOUS PROTON PUMP INHIBITOR THERAPIES IN THE TREATMENT OF GASTRODUODENAL ULCER BLEEDING]

DÖBRÖNTE Zoltán

[Gastroduodenal peptic ulcer disease accounts for nearly 50% of the cases of acute upper gastrointestinal tract bleeding. Despite early endoscopic diagnosis and treatment, bleeding recurs in 15-20% of the cases within 72 hours. Mortality of recurrent bleeding is high (25-30%), therefore, the main goal of the treatment of patients with bleeding peptic ulcer is not only to stop the bleeding but also to prevent recurrence. The most effective way of the endoscopic therapy is the combination of injection (epinephrine) and thermal coagulation, with supplemental clip placement in spurting arterial bleeding. Overlying adherent clot should be removed after epinephrine has been injected into the ulcer base and the exposed vessel lesion should be coagulated. Proton pump inhibitors promote platelet aggregation and inhibit the proteolytic digestion of clots by raising the pH of gastric juice. The nearly neutral pH necessary for clot stability can be achieved by an intravenous bolus injection of the proton pump inhibitor followed by continuous infusion for 72 hours, after which an oral proton pump inhibitor should be used to prevent late recurrence of bleeding. Proton pump inhibitors can thus contribute significantly to the maintenance of primary haemostasis in patients with bleeding peptic ulcer. Beside omeprazole and pantoprazole that have been available as intravenous proton pump inhibitors, intravenous esomeprazole is a promising new product for the treatment of bleeding peptic ulcer since it ensures a faster and more pronounced intragastric pH increase.]

Lege Artis Medicinae

[Rebecca]

FRENKL Róbert

Lege Artis Medicinae

[Snapshot – For a Lifetime...]

FEKETE György

Lege Artis Medicinae

[In the focus: stroke]

NAGY Zoltán

Lege Artis Medicinae

[CARDIOMETABOLIC EFFECTS OF THE ANGIOTENSIN RECEPTOR BLOCKER TELMISARTAN]

WINKLER Gábor

[Telmisartan, an angiotensin receptor blocker, is a potent antihypertensive drug. Similarly to other members of the drug family, it has cardio-, vasoand renoprotective properties; in addition, uniquely in the group, it stimulates the peroxisome proliferator activated receptor (PPAR) -γ. This partial agonist activity results in favourable effects mainly in carbohydrate metabolism and, to a lesser extent, in lipid metabolism. Based on this pharmacological profile, telmisartan seems to be especially useful in the treatment of hypertension associated with metabolic syndrome or type 2 diabetes.]

All articles in the issue

Related contents

Hungarian Radiology

[Loránd Fráter - A president without position; Professor Eberhard Willich is 85 years old; My memories on Hungarians]

LOMBAY Béla, SCHLÄFFER Erzsébet, EBERHARD Willich

Journal of Nursing Theory and Practice

[Nurses Knowledge and Tasks of real Time Evacuation of Inpatient Care Institutions]

PÁPAI Dániel, PÁPAI Tibor

[In our modern, globalized world, there is a significant increase in the number of events requiring immediate action where coordinating the rescue, health care and placement of several people at the same time. Unfortunately, we can count not only on international, but domestic relations, for various mass disaster threats and events, whether it is a natural disaster or a different form of artificial disaster. It is of the utmost importance to treat such a qualified situation in inpatient care and health care institutions, where there is a large number of patients and caregivers with limited self-reliance and movement. Although it is important to emphasize the importance of disaster prevention in the domestic context, in cases requiring immediate and rapid intervention, there is a great deal of responsibility and responsibility for nursing staff. By questionnaire surveys, we investigated the catastrophic and evacuation knowledge of inpatient care nurses and the system and method of acquiring these skills. After the results were processed, we concluded that our assumptions proved that the knowledge of the target group in question was very incomplete. In order to increase efficiency, we consider it of the utmost importance to develop a procedure based on unified principles but to adapt to the local conditions of the given institution and to develop its ability-based education system. ]

Lege Artis Medicinae

[The Effects of Music Therapy on Stress and Immunity Levels ]

KOLLÁR János

LAM Extra for General Practicioners

[THE BIOLOGICAL BASIS OF SCREENING: NATURAL HISTORY OF MALIGNOUS TUMOURS]

DÖBRŐSSY Lajos, KOVÁCS Attila, BUDAI András

[The development of malignous tumours is a prolonged, multistage process. The onset of clinical symptoms and subjective complaints is preceded by the preclinical detectable phase, during which the tumour does not cause any symptoms but it has some signs and can be detected by screening. Information on the tumour’s natural history is of practical importance for choosing the screening strategy. When evaluating screening results, the various biases related to biological reasons need to be taken into consideration.]

Clinical Neuroscience

[Alemtuzumab therapy 2017]

BIERNACKI Tamás, BENCSIK Krisztina, SANDI Dániel, VÉCSEI László

[Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system comprising of inflammation, demyelinisation and neurodegeneration. The natural history of MS is heterogenous. Owing to the vast range and severity of the symptoms MS can cause the effect of the disease on one’s cognitive and physical status is unpredictable. According to the new, phenotype based classification two subgroups can be distinguished; relapsing-remitting (RR) and progressive MS. Relapsing-remitting MS can be further divided into active and inactive disease. The activity of the disease can be proven either clinically and/or by radiological means. A patient’s disease is considered inactive, if it fulfills the criteriae set in the “no evidence of disease activity-3” (NEDA-3) concept, meaning that no progression can be seen on the MRI scans, the patient is relapse free and there is no worsening on any disability scale. Nowadays a paradigm shift can be seen in the treatment of MS. The aim of this shift is to provide each and every patient with the most potent medication best suiting his/her illness as soon as possible. Alemtuzumab offers a great option as either a first line treatment or as escalation therapy for patients with a highly active disease. The efficacy of alemtuzumab was proven in two phase III trials (CARE-MS I, II), where it was compared to subcutaneous interferon b-1a, administered three times weekly. In both studies alemtuzumab was superior to subcutaneous interferon b-1a in terms of relapse rate reduction, in all scouted MRI parameters. In the CARE-MS II trial it was found superior in terms of progression slowing. In the studies’ first 2 years 32% and 39% of the alemtuzumab treated patients managed to achieve the NEDA-3 state (data from CARE-MS II and I respectively). At the end of the 4 year extension of both studies these numbers have increased to 60% and 55% respectively. The aim of our synopsis is to suggest neurologists an evidence based guideline, a therapeutic algorithm to be used when they give their MS patients the very best, personalised treatment, and also to appoint the recently introduced alemtuzumab to its proper place in the algorithm.]